AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29454039
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg selenium/d as selenium-enriched-yeast
Trial: 29454039
Drug: 200 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 µg selenium/d as selenium-enriched-yeast
Trial: 23388205
Drug: Pre-biopsy educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-biopsy educational (ED) packet containing biopsy instruction sheet and a booklet about the biopsy procedure and prostate cancer treatment decision aid
Trial: 19968611
Drug: Geranylgeranylacetone (GGA)
RxNorm normalized name: geranylgeranylacetone
DrugBank: Teprenone (DB15955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geranylgeranylacetone (GGA) 150 mg/day
Trial: 18334144
Drug: Wuling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuling Capsule (3 capsules three times a day)
Trial: 18334144
Drug: Deanxit (10.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deanxit (10.5 mg twice daily)
Trial: 18334144
Drug: Wuling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuling Capsule plus Deanxit (both treatments)
Trial: 18334144
Drug: Wuling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuling Capsule
Trial: 8473428
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (n = 10)
Trial: 8473428
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (n = 8)
Trial: 24633934
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (240 mg daily for 24 weeks)
Trial: 18004064
Drug: C.E.R.A. administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. administered once every 2 weeks (Q2W) via subcutaneous or intravenous injection
Trial: 18004064
Drug: Epoetin administered
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin administered at current dose, route, and administration interval (once to three times weekly)
Trial: 7724390
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (digoxin, furosemide, low dose ACE inhibition)
Trial: 7724390
Drug: Staged therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staged therapy (maximal tolerated ACE inhibition, PGE1 therapy, outpatient dobutamine)
Trial: 1837942
Drug: Repeated treatment
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated treatment (C3)
Trial: 7107969
Drug: Penfluridol, maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penfluridol, maximum dose 140 mg per week
Trial: 7107969
Drug: Chlorpromazine, maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine, maximum dose 7350 mg per week
Trial: 3830763
Drug: Diltiazem 240
RxNorm normalized name: diltiazem 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 240 mg/day (D240)
Trial: 3830763
Drug: Diltiazem 360
RxNorm normalized name: dilTIAZem 360 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 360 mg/day (D360)
Trial: 3830763
Drug: Nifedipine 120
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine 120 mg/day (N)
Trial: 3830763
Drug: Verapamil 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 480 mg/day (V)
Trial: 26791678
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 0.5 mg kg(‐1) day(‐1) for 10 days
Trial: 25623842
Drug: Patient and
RxNorm normalized name: JCARH125 CONSISTS OF HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CD4+ CD8+ T CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) LENTIVIRAL V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient and therapy-related factors (age, gender, bruxism, number of prostheses, time since last extraction, smoking, fit of dentures, average denture wearing time, wearing during the night)
Trial: 18375896
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg) for 3 months
Trial: 18375896
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg) for 3 months
Trial: 16683008
Drug: Terazosin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin combined with ExMI therapy (group 2)
Trial: 16683008
Drug: Terazosin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin monotherapy (group 1)
Trial: 27220960
Drug: Sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib plus Erlotinib (400 mg twice daily plus 150 mg once daily)
Trial: 27220960
Drug: Sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib plus Placebo (400 mg twice daily plus placebo)
Trial: 25100386
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (MDI) therapy
Trial: 15711353
Drug: Neoadjuvant GNRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant GNRH therapy (1.2 mg per day as nasal spray for 4 weeks)
Trial: 14658952
Drug: Risperidone treatment
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone treatment (0.02‐0.06 mg/kg/day)
Trial: 10781483
Drug: 0.5 mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg. kg(‐1) esmolol
Trial: 6424926
Drug: MMC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMC plus oral administration of Futraful for 3 months (protocol II, group B)
Trial: 6424926
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous injection of a moderate dose of MMC (protocol I, group A)
Trial: 6424926
Drug: Bolus intravenous
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intravenous injection of MMC (protocol II, group A)
Trial: 21216077
Drug: Midazolam +
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam + low-dose ketamine (0.03 mg/kg midazolam + 0.3 mg/kg ketamine + saline)
Trial: 21216077
Drug: Midazolam +
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam + placebo (0.03 mg/kg midazolam + 2 mL placebo)
Trial: 1599062
Drug: Fentanyl 0.2
RxNorm normalized name: fentanyl 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.2 mg
Trial: 2875594
Drug: Fentanyl 0.1
RxNorm normalized name: fentanyl 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.1 mg
Trial: 6399698
Drug: Adjuvant razoxane
RxNorm normalized name: razoxane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant razoxane treatment (61 patients)
Trial: 6399698
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (65 patients)
Trial: 30939778
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy activities (two different types) added to standard care for 25 weekly sessions
Trial: 19678756
Drug: hsCRP level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP level > or =5 microg/mL at baseline
Trial: 19678756
Drug: IL-6 level
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 level > or =3 pg/mL at baseline
Trial: 19678756
Drug: hsCRP level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP level > or =5 microg/mL (latest follow-up)
Trial: 19678756
Drug: amyloid-A level
RxNorm normalized name: .beta.-amyloid protein-(1-6)-peptidylglycylglycyl-L-cysteine-3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-n-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)propanamide-alanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amyloid-A level > or =6 mg/L (latest follow-up)
Trial: 19678756
Drug: IL-6 level
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 level > or =3 pg/mL (latest follow-up)
Trial: 17195936
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine
Trial: 17195936
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A or B vaccines (Control)
Trial: 15504991
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (MDII)
Trial: 11216970
Drug: Intermittent transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent transdermal nitroglycerin (NTG) 0.6 mg/h
Trial: 6777073
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA, 1.5 g/day)
Trial: 30380956
Drug: Oblique intradermal
RxNorm normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oblique intradermal suture (OIS)
Trial: 30380956
Drug: Conventional interrupted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional interrupted intradermal suture (IS)
Trial: 19390223
Drug: Treatment after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment after 6 weeks
Trial: 19390223
Drug: Post-treatment plasma
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment plasma tryptophan concentrations
Trial: 19390223
Drug: Post-treatment kynurenine
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment kynurenine concentrations
Trial: 9054789
Drug: Intravenous clomipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clomipramine
Trial: 9054789
Drug: Oral clomipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clomipramine
Trial: 9054789
Drug: Oral clomipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clomipramine after intravenous loading
Trial: 8477178
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxitropium and fenoterol
Trial: 3080920
Drug: Peripheral parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral parenteral nutrition with antiphlebitic mixture (1000 IU heparin, 5 mg hydrocortisone, and 1.8 mEq sodium hydroxide as a buffer)
Trial: 3080920
Drug: Peripheral parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral parenteral nutrition without antiphlebitic mixture
Trial: 22656405
Drug: Dexmedetomidine-Ketamine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine-Ketamine combination
Trial: 22656405
Drug: Dexmedetomidine-Midazolam combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine-Midazolam combination
Trial: 20399997
Drug: Enteric-coated flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated flurbiprofen 100-mg tablet (test)
Trial: 20399997
Drug: Film-coated immediate-release
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated immediate-release flurbiprofen 100-mg tablet (reference)
Trial: 18806023
Drug: Intraoperative low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative low-dose ketamine (bolus dose of 0.5 mg/kg followed by continuous infusion of 4 microg.kg(‐1).min(‐1))
Trial: 18806023
Drug: Intraoperative low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative low-dose ketamine
Trial: 10084101
Drug: Propofol infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol infusion, 30 mg kg‐1 h‐1
Trial: 10084101
Drug: Propofol infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol infusion, 30 mg kg‐1 h‐1 + fentanyl bolus, 2 micrograms kg‐1 i.v.
Trial: 7560599
Drug: L-arginine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (7 g three times daily for 3 days)
Trial: 7201089
Drug: Low-dose bromocriptine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bromocriptine therapy (average dose, 15 mg per day)
Trial: 7201089
Drug: Low-dose bromocriptine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bromocriptine therapy (initial dose 1 mg per day with slow escalation)
Trial: 3553878
Drug: Low-dose bromocriptine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bromocriptine therapy
Trial: 23869063
Drug: Intravenous adenosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine, 140 μg·kg(‐1)·min(‐1), during 5 min
Trial: 17425616
Drug: Ropivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 7.5 mg/ml plus isotonic sodium chloride solution
Trial: 17425616
Drug: Ropivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 7.5 mg/ml plus 100 mg tramadol
Trial: 3409620
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 200 mg of [15N]glycine as a tracer
Trial: 28961980
Drug: Probiotic adjunct
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic adjunct therapy
Trial: 27144828
Drug: Stem cells
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cells cultured on beta‐TCP in combination with rh‐PDGF‐BB
Trial: 18305079
Drug: GIK (Glucose‐insulin‐potassium)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK (Glucose‐insulin‐potassium) group
Trial: 14665656
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (levothyroxine reduced by 50 micro g/d and substituted with liothyronine, 7.5 micro g, taken twice daily for 4 months)
Trial: 14665656
Drug: Levothyroxine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine alone (usual dose)
Trial: 14665656
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (levothyroxine plus liothyronine)
Trial: 8857434
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion (6 mu g kg‐1 min‐1)
Trial: 1627200
Drug: 2% sertaconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% sertaconazole dermatological cream
Trial: 1627200
Drug: Excipient of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipient of the cream without sertaconazole
Trial: 6373426
Drug: Maximized metabolic
RxNorm normalized name: Eleutherococcus Senticosus (Rupr. Et Maxim.) Maxim. Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximized metabolic control (multiple insulin injections daily or insulin pumps)
Trial: 6373426
Drug: Standard control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard control (one or more injections of insulin daily)
Trial: 30169797
Drug: Culturally targeted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally targeted Courage to Quit (CTQ-CT) smoking cessation treatment
Trial: 21652220
Drug: Doxercalciferol capsules
RxNorm normalized name: Doxercalciferol Capsules
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxercalciferol capsules (conversion factors: 0.5, 1.0, 1.5 times the current paricalcitol dose)
Trial: 21652220
Drug: Doxercalciferol capsules
RxNorm normalized name: Doxercalciferol Capsules
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxercalciferol capsules (conversion factors: 1.0, 1.5, 2.0 times the current doxercalciferol injection dose)
Trial: 21652220
Drug: Doxercalciferol capsules
RxNorm normalized name: Doxercalciferol Capsules
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxercalciferol capsules
Trial: 17554581
Drug: Oral risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral risedronate 2.5 mg/day for 6 months
Trial: 17554581
Drug: No osteoactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No osteoactive drug (Control)
Trial: 12584837
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine combination therapy
Trial: 8181590
Drug: Pre-operative intra-arterial
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative intra-arterial chemotherapy
Trial: 8181590
Drug: More effective
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More effective drugs and less demanding regimens
Trial: 138560
Drug: Minocycline 50
RxNorm normalized name: minocycline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 50 mg twice daily
Trial: 138560
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg twice daily
Trial: 21738077
Drug: 7.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g/day TU-025
Trial: 21738077
Drug: 12.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 g/day TU-025
Trial: 8095127
Drug: Famotidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (20 mg twice daily)
Trial: 8095127
Drug: Nizatidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (150 mg twice daily)
Trial: 31538372
Drug: Osmotic-Release Oral
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic-Release Oral System Methylphenidate (OROS‐MPH)
Trial: 19006068
Drug: Real ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real ultrasound (US) treatment
Trial: 30092205
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound (US) treatment
Trial: 16261462
Drug: Flurbiprofen 50
RxNorm normalized name: flurbiprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50 mg followed immediately by propofol LCT 2 mg.kg(‐1)
Trial: 16261462
Drug: Flurbiprofen 50
RxNorm normalized name: flurbiprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50 mg followed by propofol LCT 2 mg.kg(‐1) 1 min later
Trial: 16261462
Drug: 2% Lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Lidocaine 40 mg followed immediately by propofol LCT 2 mg.kg(‐1)
Trial: 16261462
Drug: Propofol LCT
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol LCT 2 mg.kg(‐1) alone
Trial: 16261462
Drug: Propofol in
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol in a mixture of medium‐chain triglyceride (MCT) and LCT 2 mg.kg(‐1)
Trial: 11895791
Drug: Anti-Helicobacter pylori
RxNorm normalized name: Anti-Helicobacter pylori IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Helicobacter pylori treatment
Trial: 10798
Drug: Solcoseryl and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solcoseryl and Proglumide (systematic preventive treatment)
Trial: 10798
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific treatment (Control group)
Trial: 30808512
Drug: d‐Nav Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐Nav Insulin Guidance System with health‐care professional support
Trial: 28072863
Drug: 30mg/kg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/kg of oral azithromycin
Trial: 28072863
Drug: 50,000 units/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 units/kg of intramuscular benzathine penicillin
Trial: 26264718
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) >20 mg/day
Trial: 26264718
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) (all doses)
Trial: 26264718
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) ≤20 mg/day
Trial: 23794107
Drug: tolcapone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone (100 mg three times a day for 1 day and then 200 mg three times a day for 6 days)